Shattuck Labs (STTK) Expected to Post Earnings on Tuesday

Key Points

• Shattuck Labs is expected to report Q3 2026 results on Tuesday, November 10. Analysts anticipate a loss of $0.10 per share and revenue of approximately $0.03 million.
• The company reported Q2 EPS of negative $0.12, in line with consensus estimates. Analysts expect full-year and next-year losses of $0.45 and $0.49 per share, respectively.
• Shares recently traded at $5.42, while Wall Street maintains a consensus “Buy” rating and an average price target of $13.70, despite one “Sell” rating.

Shattuck Labs (NASDAQ:STTK - Get Free Report) is projected to issue its Q3 2026 resultson Tuesday, November 10th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $0.03 million for the quarter. Individuals may visit the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.12) EPS for the quarter, meeting analysts' consensus estimates of ($0.12). On average, analysts expect Shattuck Labs to post ($0.45) EPS for the current fiscal year and ($0.49) EPS for the next fiscal year.

Shattuck Labs Stock Up 2.0%

Shattuck Labs stock traded up $0.10 during midday trading on Tuesday, hitting $5.42. 61,072 shares of the stock were exchanged, compared to its average volume of 965,515. The stock has a market capitalization of $544.47 million, a PE ratio of -10.64 and a beta of 1.09. The company has a fifty day simple moving average of $6.24 and a two-hundred day simple moving average of $6.02. Shattuck Labs has a 52 week low of $1.72 and a 52 week high of $8.33.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Raymond James Financial initiated coverage on shares of Shattuck Labs in a report on Monday, August 24th. They issued a "strong-buy" rating and a $18.00 target price on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Shattuck Labs in a report on Friday, September 11th. Needham & Company LLC upped their price objective on shares of Shattuck Labs from $17.00 to $19.00 and gave the company a "buy" rating in a research report on Friday, October 2nd. JPMorgan Chase & Co. began coverage on Shattuck Labs in a research note on Friday, July 24th. They set an "overweight" rating and a $10.00 price objective on the stock. Finally, UBS Group assumed coverage on Shattuck Labs in a report on Sunday, October 11th. They set a "buy" rating and a $17.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Shattuck Labs has a consensus rating of "Buy" and an average target price of $13.70.

About Shattuck Labs

Shattuck Labs, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company's research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to combine immune-cell activation with checkpoint inhibition in a single therapeutic molecule.

Shattuck's pipeline has included bifunctional fusion proteins such as SL-172154, an investigational therapy designed to engage CD40 ligand and block PD-L1, and SL-173154, which is designed to target CD27 ligand and PD-L1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.